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Highly stable PEGylated gold nanoparticles in water:
applications in biology and catalysis†
Kamil Rahme,*abc Marie Therese Nolan,d Timothy Doody,e Gerard P. McGlacken,d
Michael A. Morris,ab Caitriona O'Driscolle and Justin D. Holmesab
Here we report the synthesis of well dispersed gold nanoparticles (Au NPs), with diameters ranging
between 5 and 60 nm, in water and demonstrate their potential usefulness in catalysis and biological
applications. Functionalised polyethylene glycol-based thiol polymers (mPEG-SH) were used to stabilise
the pre-synthesised NPs. Successful PEGylation of the NPs was confirmed by Dynamic Light Scattering
(DLS) and zeta potential measurements. PEG coating of the NPs was found to be key to their colloidal
stability in high ionic strength media, compared to bare citrate-stabilised NPs. Our results show that
PEG–Au NPs with diameters <30 nm were useful as catalysts in the homocoupling of arylboronic acids in
water. Additionally, PEG–Au NPs were also shown to be stable in biological fluids, non-cytotoxic to
B16.F10 and CT-26 cell lines and able to successfully deliver siRNA to CT-26 cells, achieving a significant
reduction (p < 0.05) in the expression levels of luciferase protein; making these NPs attractive for further
biological studies.
Introduction
The increasing progress of nanotechnology in the last few
decades has made nanomaterials indispensable in many areas
such as materials science, medicals, and cosmetics.1–3 Nano-
particles (diameter 1–100 nm) exhibit particular properties
that arise from quantum size effects and also from a high
surface to volume ratio.1,4,5 Their small size enables them to
interact with biomolecules (such as enzymes, antibodies, DNA,
proteins etc.) and cells.6 As such, they are of appropriate
dimensions for applications in nanobiotechnology and catal-
ysis.7–9 Noble metal nanoparticles, especially gold, are well
known for their characteristic surface plasmon resonances
which form the basis for many biological sensing and imaging
applications.1,4,10–13 Besides their potential applications in
biology, the catalytic application of gold nanoparticles (Au
NPs) in organic reactions has also been of considerable
interest in recent years. Important transformations using Au
catalysis, such as the selective oxidation of alcohols,14–16 CO
oxidation in the absence of H2,17–19 chemoselective reduction
of nitroarenes,20 and a wide variety of commercially important
synthetic protocols have been studied exstensively.21–23
Researchers have also shown that poly(2-aminothiophenol)
(PATP)-supported Au NPs can be used in Suzuki–Miyaura
cross-coupling reactions.24 More recently, the homocoupling of
arylhalides has been accomplished using a catalytic system
comprising of Au NPs supported on a bifunctional periodic
mesoporous organosilica.25 Aryl boronic acids have also been
homocoupled using Au on solid supports through apparent
heterogeneous conditions. Homocoupling with high selectivity
was achieved using Au supported on CeO2.26 The application of
nanoparticles in biology and catalysis typically requires them
to be well dispersed and stable in solution, which can be
difficult due to their high surface energies.27 Due to this
instability, especially in the presence of salts, NPs can lose
their size-dependent properties (catalytic, optical, magnetic
etc.) caused by the high tendency of adhesion and aggrega-
tion.28 Aggregation of nanoparticles is much more pronounced
in solvents with high ionic strengths, i.e. biological uids.12
Therefore, the dispersion of NPs must be controlled to provide
a better platform for the advancement of these materials in
catalytic and biological applications.29 In this manuscript we
report the synthesis of stable colloidal Au NPs in water and
under physiological conditions (0.15 M NaCl), achieved by
attaching polyethylene glycol-based thiol polymers (mPEG-SH)
as a stabilising ligand to the surfaces of Au NPs, via thiol
linkages. PEG was the ligand of choice due to its ability to
inhibit non-specic interactions with proteins in biological
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applications, as well as its compatibility with a diverse set of
solvents (water, DMSO, THF etc.).30,31 Further applications
of Au NPs–PEG were demonstrated in the homocoupling of
boronic acids in water.32,33 Our data shows that the PEG–Au
NPs, with diameters <30 nm, were useful as catalysts in the
homocoupling of arylboronic acids in water, while PEG–Au
NPs, with diameters of 60 nm, and Au NPs–citrate nano-
particles of different sizes (5, 15, 30 and 60 nm) had minimal
catalytic efficiency. Moreover, the catalytic efficiency of 15 nm
Au NPs–PEG10000, expressed in term of the yield of pure 4-
methoxyphenylboronic acid, was found to increase from 6 to
60% when the amount of Au NPs increased from 0.48 to 5
mol%. Finally, the PEG–Au NPs were complexed with siRNA
and also tested for toxicity on B16.F10 and CT-26 cell lines,
either alone or in the presence of siRNA, and for their aptitude
in delivering siRNA to CT-26 cell lines.
Experimental
Chemicals and materials
Puried H2O (resistivity z 18.2 MU cm) was used as a solvent.
All glassware was cleaned with aqua regia (3 parts of concen-
trated HCl and 1 part of concentrated HNO3), rinsed with
distilled water, ethanol, and acetone and oven-dried before use.
Tetrachloroauric acid trihydrate (HAuCl4$3H2O), sodium citrate
(C6H5Na3O7$2H2O), sodium borohydride (NaBH4) and ascorbic
acid were purchased from Sigma Aldrich. Thiol terminated
poly(ethylene glycol) methyl ether,Mw ¼ 2100, 5400, 10 800 and
20 800 g mol1 were purchased from Polymer Source. All
products were used as received.
Preparation and PEGylation of gold nanoparticles
Diameter of 5  1.5 nm Au NPs. To an aqueous solution (150
mL) of HAuCl4$3H2O (0.25 mmol L
1) was added 2.5 mmol of a
200 mM mPEG-SH (Mw ¼ 10 800 g mol1) solution and the
mixture was stirred vigorously. To this solution was added an
ice cold solution of NaBH4 in order to have a nal concentration
of 0.25 mmol L1 NaBH4. Aer addition of NaBH4, an instan-
taneous colour change from pale yellow to deep red was noted.
The Au NPs obtained with this procedure were approximately
5  1.5 nm.
Diameter of 15  1.5 nm Au NPs. 150 mL of an aqueous
solution of HAuCl4$3H2O (0.25 mmol L
1) was heated to 95 C
with stirring. 0.53 mL of a 340 mmol L1 sodium citrate
aqueous solution was rapidly added. The colour of the solution
changed from pale yellow to dark blue, and then to deep red-
burgundy within about 8 min. Stirring and heating was main-
tained during 1.5 h aer addition of sodium citrate. The heat
was then removed and the solution was kept under stirring,
until cooled to room temperature. The Au NPs obtained with
this procedure were 15  1.5 nm.
Preparation of 30  4 nm and 60 nm  8 nm Au NPs. For
Au NPs, larger than 15 nm, a weak reducing agent ascorbic acid
was used. For30 nm Au NPs, 150 mL of an aqueous solution of
HAuCl4$3H2O (0.25 mmol L
1) and 1 mmol L1 sodium citrate
was stirred vigorously. To this solution was added a volume of
ascorbic acid in order to have a nal concentration of 0.38
mmol L1. Aer addition of ascorbic acid the colour of the
solution changed from pale yellow to dark blue, and then to
deep red-burgundy in less than 1 min. Stirring and was main-
tained for 1 h. The Au NPs obtained were 30  4 nm. By
increasing the concentration of ascorbic acid to 1 mmol L1,
added in 2 amounts (0.5 each), Au NPs 60 nm  8 nm were
obtained, we note that these Au NPs were less monodisperse.
Graing of poly(ethylene glycol) ligands. Thiolated poly-
ethylene glycol (mPEG-SH) was covalently graed to the surface
of the Au nanoparticles. A solution of mPEG-SH of the desired
molecular weight was added to a solution of citrate-capped Au
nanoparticles with stirring. The solution was stirred for 1 h
allowing citrate ligands to exchange with mPEG-SH. The excess
mPEG-SH was removed via centrifugation at 15 000 rpm for
about 45 min. Thiol groups are known to have a strong affinity
for Au, resulting in covalent attachment of PEG to the Au
nanoparticles. The resulting colloidal solutions were very stable
for several months, as well as in high ionic strength solvents
and biological uids, furthermore they were able to undergo
ltration and freeze drying.
UV-visible spectroscopy
Optical absorption spectra were obtained on a CARY UV-visible
spectrophotometer with a xenon lamp (300–900 nm range, 0.5
nm resolution).
Dynamic light scattering and zeta potential measurements
The pristine solutions of Au and PEGylated Au nanoparticles,
were diluted by 5 to 10 times depending on the initial
concentration (absorption range 0.2–0.5) prior to dynamic light
scattering (DLS) measurements. The measurements were
undertaken with the Malvern instrument (Zetasizer Nano
Series) at 25 C using the default non-invasive back scattering
(NIBS) technique with a detection angle of 173. Three
measurements were made per sample and the standard devia-
tion (s) was calculated, typically s ¼ 1–2 nm.
Transmission electron microscopy
Citrate and PEG-stabilised Au nanoparticles were placed on
carbon-coated copper grids (Quantifoil, Germany) and dried
over night in air, prior to transmission electron microscope
(TEM) inspection. The samples were inspected using a JEOL
JEM-2100 TEM operating at 200 kV. All the micrographs were
recorded on a Gatan 1.35k  1.04k  12 bit ES500W CCD
camera. TEM images were analysed using Image J soware.
Scanning electron microscopy
Citrate and PEG-stabilised gold nanoparticles were deposited
from solution on a silicon wafer and dried in air prior to
inspection by scanning electron microscope (SEM). The
samples were inspected using a FEI 630 NanoSEM equipped
with an Oxford INCA energy dispersive X-ray (EDX) detector,
operating at 5 kV.

















































General protocol for homocoupling: characterisation data
Synthesis of biphenyl.
In a round bottom ask (100 mL) equipped with a condenser
and magnetic stirrer bar, phenylboronic acid (2 mmol) and
NaOH (8 mmol) were mixed with 15 nm Au NP–PEG2000 (2
mol%) in H2O (40 mL). The resulting mixture was stirred at
80 C for 48 h. The crude reaction mixture was then extracted
with ethyl acetate (3  20 mL). The organic layers were
combined and washed with 10% aqueous NaOH solution,
dried with MgSO4, ltered and concentrated under reduced
pressure to afford the pure product (67 mg, 44%) as a white
solid, m.p. 67–68 C (ref. 2 67–69 C); lmax/cm
1 (KBr): 3034,
1943, 1569, 1480, 1429, 729, 696; dH (300 MHz) 7.61–7.57 [4H,
m], 7.46–7.41 [4H, m], 7.39–7.31 [2H, m]; dC (CDCl3, 75.5 MHz)
141.26, 128.8, 127.3, 127.2.
Synthesis of 4,40-dimethoxybiphenyl.
In a round bottom ask (100 mL) equipped with a condenser
and magnetic stirrer bar, para-methoxy boronic acid (1 mmol)
and NaOH (2 mmol) were mixed with 15 nm Au NP–PEG10000
(5 mol%) in H2O (25 mL). The resulting mixture was stirred at
80 C for 22 h. The crude reaction mixture was then extracted
with ethyl acetate (3  20 mL). The organic layers were
combined and washed with 10% aqueous NaOH solution, dried
with MgSO4, ltered and concentrated under reduced pressure
to afford the pure product (64.2 mg, 60%) as a white solid, m.p.
168–169 C (ref. 3 168–170 C); lmax/cm
1 (KBr):4 2958, 1500,
1439, 1276, 1249, 1041; dH (300 MHz) 7.49–7.45 [4H, m], 6.98–
6.93 [4H, m], 3.84 [6H, s]; dC (CDCl3, 75.5 MHz) 158.7, 133.5,
127.7, 114.2, 55.4.
NMR spectroscopy (NMR)
NMR spectra were run in CDCl3 using tetramethylsilane
(TMS) as the internal standard. 1H NMR spectra were recor-
ded at 300 MHz on a Bruker AVANCE 300 spectrometer. 13C
NMR spectra were recorded at 75 MHz on a Bruker AVANCE
300 instrument.
Infra-red spectroscopy (IR)
IR spectra were recorded on a Perkin-Elmer FT-IR Paragon 1000
spectrophotometer. Solid samples were dispersed in potassium
bromide and recorded as pressed discs.
Melting points
Melting points were measured in a Thomas Hoover Capillary
Melting Point apparatus.
Dynamic light scattering and zeta potential measurements in
the presence of biomolecules
Au–PEG particles were complexed with siRNA or siRNA : prot-
amine at a molar ratio of 1 : 10. Samples were complexed for 1 h
and subsequently diluted in either double distilled H2O or in
Dulbecco's modied eagle's medium without phenol red
(Sigma-Aldrich) prior to DLS and zeta potential analysis.
Measurements were performed using a Zetasizer Nano from
Malvern instruments at 25 C (back scattering at 173 NIBS
default). The model used in the tting procedure was provided
by the instrument (using Mark Houwink parameters and
cumulative t). The standard deviation was calculated by per-
forming three measurements on each sample.
Cell culture, cytotoxicity and in vitro siRNA knockdown
MTT cytotoxicity assay. The murine melanoma stably
expressing pGL4 luc2 lentivirus, B16-F10-luc2 (Caliper Life
Sciences, Hopkinton, MA) were routinely cultured in RPMI 1640
supplemented with 10% foetal bovine serum and grown in 5%
CO2 at 37 C. Prior to cytotoxicity determination cells were
seeded at a density of 4  104 cells in a 96-well plate and grown
in complete media for 24 h. Cell viability was determined by the
MTT assay which measures the reduction of MTT to formazan
by mitochondrial reductase enzymes giving a purple colour. Au
NPs alone and protamine condensed siRNA (50 nM) complexed
with Au nanoparticles, were added to the cells and incubated for
4 h. The medium was removed and replaced with fresh
complete medium containing MTT ((3-(4,5-dimethylthiazole-2-
yl)-2,5-diphenyltetrazolium) bromide) (Sigma) at a working
concentration of 0.5 mg mL1. Aer 4 h of incubation the cell
culture medium was removed, and the formazan crystals
produced were dissolved in 100 mL DMSO for 5 min at room
temperature. Absorbance was read at a wavelength of 590 nm. A
similar procedure described above was also performed on
murine colon carcinoma cell line, CT26. All experiments were
performed in triplicate.
In vitro siRNA knockdown
Cell culture and in vitro siRNA knockdown. The murine
colon carcinoma cell line, CT26, was obtained from the Amer-
ican Type Culture Collection (ATCC). Cells were maintained in
Dulbecco's modied Eagle medium (Sigma) supplemented with
10% fetal bovine serum (Sigma). Cells were grown in 5% CO2 at
37 C. For in vitro siRNA knockdown, cells were seeded, 24 h
prior to transfection at a density of 5  104 cells in a 24 well
plate. Cells were transfected with luciferase reporter plasmid,
pGL3Luc (1 mg per well) complexed with Lipofectamine 2000
(3 mL mg1 DNA) for 2 h. Cells were then washed twice with PBS
prior to siRNA transfection. Luc GL3 siRNA (50 nM), was
condensed with protamine (MR5 – mass ratio), and subse-
quently complexed with Au NP's (MR10) or Lipofectamine 2000

















































(1 mL mL1 siRNA). Luc GL3 siRNA alone and non-silencing
siRNA were used as control. Aer 4 h, complexes were removed
and fresh medium was added to each well. Cells were incubated
for a further 20 h and luciferase was determined using a lucif-
erase assay kit (Promega) according to the manufacturer's
instructions. Luciferase expression levels were normalised to
cell protein content as determined by BCA (bicinchoninic acid)
protein assay (Pierce). Experiments were carried out in
triplicate.
Fluorescence microscopy
CT26 cells were seeded at a density of 5  104 per well on glass
cover slips in a 24 well plate and grown for 24 h. Prior to
addition of particles, cells were washed and fresh media was
added. Fluorescently-labelled protamine condensed siRNA,
complexed with Au NP's at MR 10, and control formulation
(protamine condensed siRNA), were added to the cells and
incubated for 20 h. The media was subsequently removed and
the cells washed with cell scrub buffer (AMS Biotechnology).
The cells were xed for 15 min at room temperature in 3%
paraformaldehyde (PFA). The coverslips were washed twice with
1 PBS at room temperature. Free aldehyde groups were
quenched with 50 mM NH4Cl solution at room temperature.
Following two more washes with 1 PBS, the coverslips were
mounted on glass slides. Association of the particles with cells
was assessed by uorescent detection of the labeled siRNA
using a Nikon Eclipse TS100 invertedmicroscope equipped with
uorescein and DAPI lters and Metamorph version 6.1
soware.
Results and discussion
Preparation and characterisation of PEG–Au NPs
Au NPs were synthesised with mean diameters of 5  1.5 nm,
15 1.5 nm, 30 4 nm and 60 8 nm in water by the controlled
chemical reduction of a HAuCl4 solution. Different reducing
agents were used to produce Au NPs in this study; the strong
reducing agent sodium borohydride (NaBH4) was used at room
temperature to produce Au NPs with a mean diameter of 5 nm;
sodium citrate, a mild reducing agent, was used at high
temperature to produce 15 nm Au NPs, and nally ascorbic
acid, a weak reducing agent, was used at room temperature to
produce Au NPs with mean diameters of 30 and 60 nm.34–37 The
physical properties of the AuNPs synthesised were characterised
using UV-visible spectroscopy and either TEM or SEM (Fig. 1).
The UV-visible data clearly show that the NPs synthesised
exhibited sizedependent optical properties, resulting ina shiof
the surface plasmon resonance (SPR) band from a wavelength of
514 to 534 nm, as the mean diameter of the Au NPs increased
from 5 to 60 nm respectively.4 TEM and SEM analysis of the NPs,
utilising Image J soware, showed a size polydispersity below
20%, with the exception of the 60 nm Au NPs (30%). Electro-
statically-stabilised NPs are very sensitive to changes in pH and
ionic strength.12,29,38 Therefore, to maintain an adequate
dispersion of Au NPs in high ionic strength media, they were
coated with the PEG-SH capping ligand directly aer synthesis.
The stability of the PEG–Au NPs under physiological conditions
(0.157 mol L1 NaCl), was monitored by UV-visible spectroscopy
(Fig. 2) and the number of PEG-SH ligands needed to coat the
surface of a Au NP of a particular diameter was estimated.39 The
graing density was also determined by TGA and TEM.39 Our
data have shown that Au NPs–PEG hybrids were very stable when
compared to bare citrate-stabilised Au NPs in the presence of
NaCl (see ESI, Fig. S1†). Following the addition of salt to the
citrate-stabilised Au NPs, the initial red colour of the colloidal
solution immediately turned blue, due to a shi of the SPR peak
at 520 nm to 532 nm, with the immediate appearance of a
secondband at690nmaer 1minute, attributed to a change in
the dispersion of the Au NPs–citrate solution in the presence of
NaCl (0.157 M). A further shi to higher wavelength, 710 nm
aer 20 minutes, 722 aer about 1 hour and nally 734 nm
aer 2 hours, was also observed. This continuous shi was
accompanied by a decrease in the absorption of the overall UV-
visible spectra over time (Fig. 2a), that canbeattributed to citrate-
stabilised Au NPs aggregation.12,29,40 No nanoparticles were
observed in solution aer 3–4 hours and a black precipitate was
detected visually aer this time period (Fig. 2a). However, the
PEG-stabilised AuNPs were only slightly affected by the addition
of salt to the dispersion andno colour change of the solutionwas
observed (Fig. S1†), due to their high stability in high ionic
strength conditions. Fig. 2b shows the spectrum of Au NPs–
PEG10000 before (t ¼ 0), 1 minute, 3 and 24 hours aer adding
NaCl. The successful PEGylation of the Au NPs was also
conrmed by DLS/zeta potential measurements in the presence
of salt. Fig. 3a shows DLS analysis for 15 nm Au NPs function-
alised with various mPEG-SH molecular weight ligands at
different polymer concentrations. The mean diameter of the Au
NPs was observed to increase with the PEG concentration in all
cases. This increase was more pronounced as the length of the
PEG capping ligand increased, i.e. Au NPs–citrate size increased
from19.8 to 41 nmwhen coatedwith PEG10000. However, the size
increase was less pronounced with the shorter PEG2000, indi-
cating that more polymer was graed onto the Au NPs before
reaching surface saturation (plateau). A similar trend was seen
for the zeta potential measurements Fig. 3b. We note that TGA
used in a previous study, also showed that the number of PEG
ligands graed on 15 nm Au NPs increased when the PEG
length decreased.39 The hydrodynamic diameter increases with
the PEG length inducing a thicker PEG layer which shields the
surface charges, providing good stability.12,29,39,40 In addition, the
PEG–Au NPs did not aggregate signicantly in the presence of
NaCl and other salts. DLS/zeta combined with TEM analysis,
provided full characterisation of the colloidal dispersion for
further applications.
PEG–Au NPs catalytic efficiency
We initially tested bare 5, 15, 30 and 60 nm Au NPs–citrate as
catalysts under Suzuki–Miyaura-type conditions. When bro-
mobenzene, phenyl boronic acid and NaOH were heated in
water (95–100 C) the colour of the solution changed from red to
blue, indicating that the citrate-stabilised Au NPs aggregated
under these conditions. In all experiments, less than 2%

















































conversion to biaryl products was observed, similar results of
about 2% conversion were also obtained in the absence of Au
NPs, indicating that Au NPs–citrate has no catalytic efficiency
under the above conditions. Similarly, Au NPs, with a mean
diameter of 15nm and stabilised by PEG-SH 10800, were tested
under Suzuki–Miyaura-type conditions. Again, we observed that
a signicant amount of starting materials remained unreacted
as judged from analysis of the NMR spectra of our crude reac-
tion mixture. However pure biphenyl was isolated in trace
amounts (2%, Scheme 1). To test if homocoupling rather than
cross-coupling was occurring, we repeated the reaction using
bromobenzene and p-MeO-phenylboronic acid. To our surprise
no cross-coupled product was observed with only homocoupled
product observed, arising from homocoupling of p-MeO-phe-
nylboronic acid, isolated in 9% yield.
Based on these data, a number of optimisation experiments
were undertaken, as shown in Table 1, for the homocoupling of
para-methoxyphenylboronic acid. In order to test the effect
of the concentration of the Au catalyst on the reaction yield,
15 nm Au NPs–PEG10800 were used for the homocoupling of
p-methoxyphenyl boronic acid in the presence of sodium
hydroxide. The Au catalyst loading was varied (4.87, 6.25, 10, 25
and 50 mmol or 0.48, 0.62, 1, 2.5 and 5 mol%) and the isolated
yield of the pure 4,40-dimethoxybiphenyl product was found to
be 6, 9, 25, 49 and 60% respectively (Fig. 4). Finally, to check the
effect of the PEG length, Au NPs–PEG10800 were compared to the
Au NPs–PEG20800 in the homocoupling reaction of p-methox-
yphenylboronic acid and under similar conditions; our results
did not show a big difference in the yield obtained of the pure
products.
Stability in biological media and in the presence of
biomolecules, Au NPs/cells interaction, and cytotoxicity
PEG–Au NPs were complexed with siRNA in order to test their
toxicity in the presence and absence of siRNA. Due to the
Fig. 1 (a) UV-visible spectra, and (b) TEM/SEMmicrographs of the Au NPs–citrate with diameter 5 nm (top left); 15 nm (top right); 30 nm (bottom left) and 60 nm
(bottom right) obtained in this study.
Fig. 2 Effect of salt (0.157 M NaCl) followed by UV-visible spectroscopy. (a) Au NPs–citrate, (b) Au NPs–PEG10800. The pictures of the colloidal solutions in the middle
show the high stability of the PEG–Au NPs colloidal solution in high ionic strength conditions, compared to Au NPs–citrate that are aggregated and precipitated.

















































anionic nature of the Au NPs, negatively charged naked siRNA
would not readily bind to the particles. To allow binding, GL3
luciferase siRNA was rst complexed with protamine (a posi-
tively charged peptide) at MR 5 producing complexes with an
overall positive charge facilitating electrostatic interaction with
the negatively charged nanoparticles. Zeta potential measure-
ments showed an increase in charge from 1.9  1.4 mV for
siRNA alone, to 42  1.15 mV when complexed with protamine.
Complexes were produced with a range of Au NPs at MR 10
(Au:(siRNA:protamine)). These complexes exhibited a nearly
neutral surface charge, and their sizes were slightly increased
when compared to uncomplexed Au NPs (see Table S1†).
The viability of CT26 (ref. 39) and B16.F10 cells aer treat-
ment with the Au NPs was determined by the MTT assay. Cells
were treated with a range of Au NPs complexed with protamine
condensed siRNA at biologically active concentrations (Fig. 5).
None of the PEG-coated Au nanoparticles synthesised in this
study exhibited any cytotoxicity in B16.F10 or CT26 cell cultures,
either alone or complexed with siRNA.39 Association with cells is
vital for NP-aided siRNA delivery. The protamine:siRNA
complexation to the Au NPs does not have a signicant effect on
the toxicity of Au NPs. Protamine:siRNA on its own also does not
exhibit any toxicity. The physical characteristics of the PEG–Au
NPswere conserved aer complexationwith siRNA/protamine as
no change in the colour of the colloidal solutions was observed
aer bioconjugation. However, a slight increase in the diameter
of the 15 nm Au nanoparticles was observed aer complexation
with siRNA/protamine, as conrmed by DLS (Table S1†). The
increase in the NP diameter was most likely due to weak inter-
actions between neighbouring nanoparticles. However, this
interactionwasnot strong enough to release the ligands from the
surface of the NPs to allow direct core–core interaction.
Complexation with siRNA, characterization, and siRNA
delivery
PEG–Au NPs were complexed with siRNA in order to test their
usefulness as a delivery vector. Due to the anionic nature of the
Au nanoparticles negatively charged, naked siRNA will not
readily bind to the particles. To allow binding, GL3 luciferase
siRNA was rst complexed with protamine (a positively charged
peptide) at MR 5 producing complexes with an overall positive
charge facilitating electrostatic interaction with the negatively
charged nanoparticles. Zeta potential measurements showed an
increase in charge from 1.9  1.4 mV for siRNA alone, to 42 
1.15 mV when complexed with protamine. Complexes were
produced with a range of Au NPs at MR 10 (Au:(siRNA:prot-
amine)). These complexes exhibited a positive surface charge,
and their sizes were slightly increased when compared to
uncomplexed Au NPs. For example, the 15 nm PEG2100 particles
increased in size from 28  1.5 nm (Table 1) to 46.95  5.25 nm
upon complexation of siRNA. A similar increase in size was
noted when complexes were measured in transfection media
(15 nm PEG2100 size increased to 138  4.19). This increase was
not, however, seen for larger Au NPs, e.g. the size of 30 nm
PEG10800 was 72.8  4 nm before complexation, 69.69  0.5 nm
Fig. 3 (a) Size distribution by volume and zeta potential (b) of 15 nm Au NPs–PEG hybrids as a function of mPEG-SH polymer concentration expressed in mmol L1, for
mPEG-SH with Mw 2100; 5400; and 10 800 g mol
1.
Scheme 1 Gold-catalyzed heterocoupling reaction of bromobenzene with phenylboronic acid or 4-methoxyphenylboronic acid.

















































aer siRNA complexation and 69.91  0.6 nm when measured
in transfection media. When assessing the loading of siRNA to
cationic particles a gel retardation assay can be utilised.41,42 This
method cannot, however, be utilised in the case of protami-
ne:siRNA binding to the Au particle as the complexation of the
siRNA with protamine itself causes gel retardation and protects
the siRNA from EtBr intercalation. Further studies to determine
the extent of binding of the protamine:siRNA complex will be
carried out in the future and these studies will include modied
gel retardation assays and UV analysis of the complexes.
The association with cells is vital for NP-aided siRNA
delivery.43–45 The protamine:siRNA complexation to the Au NPs,
as mentioned above, does not have a signicant effect on the
toxicity of the Au NPs. Protamine:siRNA on its own also does not
exhibit any toxicity. In addition the protamine:siRNA complex
at the MR used here does not display and knockdown effects
when not complexed with Au NPs. TheMR used was chosen as it
introduces the charge change necessary for interaction with the
Au NPs rather than for any inherent transfection effects.
However, the siRNA–protamine loading used here is sufficient
for transfection studies.45 To examine this, uorescent siRNA
was complexed with PEG–Au nanoparticles as before, and their
association with CT26 cells was assessed by uorescence
Table 1 Homocoupling of MeO-PhB(OH)2 whereby MeO-PhB(OH)2 and PhBr were heated in the presence of NaOH and water





MeO-PhB(OH)2 10 800 NaOH 6 nm 80 C/25 h 0 : 1 : 4.9
MeO-PhB(OH)2 10 800 NaOH 30 nm 80 C/25 h 0 : 1 : 10.3
MeO-PhB(OH)2 10 800 NaOH 60 nm 80 C/25 h 1 : 1 : 23
MeO-PhB(OH)2 5400 NaOH 15 nm 80 C/25 h 0 : 1 : 4.7
MeO-PhB(OH)2 20 800 NaOH 15 nm 80 C/25 h 0 : 1 : 4.5
aMeO-PhB(OH)2 20 800 Na2CO3 15 nm 80 C/25 h 30 : 1 : 0
bMeO-PhB(OH)2 20 800 Na2CO3 15 nm 80 C/25 h 2.1 : 1 : 0.4
MeO-PhB(OH)2 5400 Cs2CO3 15 nm 80 C/20 h 4.6 : 1 : 7
a Solvent EtOH–water. b Solvent toluene.
Fig. 4 Effect of catalyst concentration on the isolated yield for the homocou-
pling of p-methoxyphenyl boronic acid alone.
Fig. 5 Effect of Au–PEG complexes on B16.F10 cell viability. Cells were incubated with a range of Au–PEG:(siRNA:protamine) complexes or Au–PEG alone at a MR of
1 : 10 for 4 hours at 37 C. A MTT assay was subsequently carried out and cell viability is expressed as % of dehydrogenase activity relative to untreated control.

















































microscopy (Fig. 6).46,47 All of the tested Au NP formulations
showed a good level of interaction, as evidenced by the green
staining in the images (Fig. 6b–d). Protamine condensed siRNA
alone showed negligible uptake (Fig. 6a) indicating the inability
of siRNA alone to associate with cells. Transfection efficiency
and gene silencing can be determined by measuring the
reduction in the expression of a reporter gene, such as lucif-
erase. GL3 luciferase siRNA was condensed with protamine and
complexed with the PEG–Au nanoparticles. Knockdown in
levels of luciferase protein expression48 was seen with all of the
PEG–Au complexes (30–50%) (Fig. 7) and signicant knock-
down, compared with the untreated control was seen with 4
particles; 15 nm-PEG2100, 15 nm-PEG5400, 30 nm-PEG10800 and
60 nm-PEG10800 (p < 0.05 – Student t-test). This compares
favourably with the commercial siRNA delivery vector, Lip-
ofectamine 2000, which achieved a knockdown of 60%. No
signicant knockdown was observed with non silencing siRNA,
conrming the specic nature of the siRNA. None of the PEG–
Au NPs synthesised in this study exhibited any cytotoxicity in
CT-26 cell cultures, either alone or when complexed with siRNA.
The slightly negatively charged PEG–Au NPs produced in this
study were able to interact electrostatically with protamine
condensed uorescent siRNA, allowing cellular association of
the complexes to be monitored by uorescence microscopy. The
physical characteristics of the PEG–Au NPs were conserved aer
complexation with siRNA/protamine, as no change in the colour
of the colloidal solutions was observed aer bioconjugation.
However, a slight increase in the size of the NPs aer
complexation with siRNA/protamine was detected by DLS, most
likely due to weak interactions between neighboured nano-
particles; however, this interaction was not strong enough to
release the ligands from the surface of the nanoparticles to
allow direct core–core interaction. A net positive charge was
measured for the Au NPs complexed with siRNA/protamine,
making these suitable candidates for cellular delivery by inter-
action with the negatively charged plasma membrane. Data
from cell association, as determined by uorescence, and siRNA
delivery, as determined by luciferase knockdown indicate that
the particles are effective at associating with and entering cells.
Conclusions
Electrostatically-stabilised Au NPs–citrate have very limited
applications due to their fast aggregation in complex media
such as the presence of a high concentration of salts which is
the main cause of this aggregation. However, steric stabilisation
of Au NPs with PEG polymer offers a high degree of stability to
the Au NPs dispersion. Au NPs–PEG hybrids were shown here to
catalyse aryl homocoupling reactions in water, although no
clear conversion was observed with 60 nm diameter NPs. The
yield of the homocoupling reaction of p-methoxyphenyl boronic
was found to increase with Au NPs–PEG loading, demonstrating
the catalytic efficacy of the Au NPs–PEG in the catalytic homo-
coupling of boronic acids. Finally, all of the Au NP–PEG hybrids
tested here were checked for cytotoxicity on B16.F10 and CT26
cell lines, and were found to be non-cytotoxic and able to deliver
siRNA into the cells. Further studies to attach biomolecules on
PEG–Au NPs and their interactions with platelets are now in
progress in order to use these NPs in active targeting and
receptor mediated delivery.
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